Rheumatology, Osteoarthritis
1. Apr 2021
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial
ABSTRACT
Objective: To assess pain outcomes and cartilage thickness change in a subgroup at risk (SAR) of further progression in the FORWARD trial of knee osteoarthritis patients treated with sprifermin.
Methods: Patients were randomised 1:1:1:1:1 to: sprifermin 100 µg every 6 months (q6mo), 100…
Read the publication
Journal:
Authors:
- Guehring H,
- Moreau F,
- Daelken B,
- Ladel C,
- Guenther O,
- Bihlet AR,
- Wirth W,
- Eckstein F,
- Hochberg M,
- Conaghan PG,